Autolus Therapeutics plc (Nasdaq: AUTL), a biopharmaceutical company focused on T cell therapies, announced updated long-term data from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The data, which includes follow-up of up to approximately three years, will be presented at the European Hematology Association (EHA) Congress in Milan, Italy, from June 12-15, 2025. The study reports a median duration of response of 42.6 months, with over half of patients remaining in remission at 24 months. Additionally, 38% of ongoing responders did not require subsequent therapy by month 33, suggesting that a portion of patients may not need further treatment after receiving obe-cel. The presentation will cover factors associated with sustained remission and survival, including Philadelphia chromosome-positive status and ongoing CAR T-cell persistence.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.